JP2013521287A5 - - Google Patents

Info

Publication number

JP2013521287A5

JP2013521287A5 JP2012556123A JP2012556123A JP2013521287A5 JP 2013521287 A5 JP2013521287 A5 JP 2013521287A5 JP 2012556123 A JP2012556123 A JP 2012556123A JP 2012556123 A JP2012556123 A JP 2012556123A JP 2013521287 A5 JP2013521287 A5 JP 2013521287A5

Authority

JP

Japan

Prior art keywords

imaging

calcium channel

type calcium

channel inhibitor

imaging marker

Prior art date

2011-02-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000003384 imaging method Methods 0.000 claims description 59
• 239000003550 marker Substances 0.000 claims description 34
• 238000000034 method Methods 0.000 claims description 27
• 241000124008 Mammalia Species 0.000 claims description 20
• 201000010099 disease Diseases 0.000 claims description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
• 206010028980 Neoplasm Diseases 0.000 claims description 11
• HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical group C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims description 7
• 229960004438 mibefradil Drugs 0.000 claims description 7
• 206010010904 Convulsion Diseases 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 238000002600 positron emission tomography Methods 0.000 claims description 4
• ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 3
• 208000006994 Precancerous Conditions Diseases 0.000 claims description 3
• 230000018199 S phase Effects 0.000 claims description 3
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
• 206010002388 Angina unstable Diseases 0.000 claims description 2
• 206010020772 Hypertension Diseases 0.000 claims description 2
• 208000007814 Unstable Angina Diseases 0.000 claims description 2
• 230000003187 abdominal effect Effects 0.000 claims description 2
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
• 230000004663 cell proliferation Effects 0.000 claims description 2
• 238000002591 computed tomography Methods 0.000 claims description 2
• 206010015037 epilepsy Diseases 0.000 claims description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
• 208000002780 macular degeneration Diseases 0.000 claims description 2
• 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
• FFEARJCKVFRZRR-JJZBXVGDSA-N methionine c-11 Chemical compound [11CH3]SCC[C@H](N)C(O)=O FFEARJCKVFRZRR-JJZBXVGDSA-N 0.000 claims description 2
• 208000004296 neuralgia Diseases 0.000 claims description 2
• 208000021722 neuropathic pain Diseases 0.000 claims description 2
• 229960005311 telbivudine Drugs 0.000 claims description 2
• DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 claims 31
• IJPVCOQVFLNLAP-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(F)=O IJPVCOQVFLNLAP-SQOUGZDYSA-N 0.000 claims 2
• 230000006369 cell cycle progression Effects 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
• 230000008051 G1/S transition checkpoint Effects 0.000 claims 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
• 210000004027 cell Anatomy 0.000 claims 1
• 230000022131 cell cycle Effects 0.000 claims 1
• 229940104230 thymidine Drugs 0.000 claims 1
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 11
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• -1 TTL-1177 Chemical compound 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229950003102 efonidipine Drugs 0.000 description 1
• HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
• 229960002767 ethosuximide Drugs 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 229940096978 oral tablet Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1